The pharmaceutical community is intrigued by retatrutide, a novel dual GIP and GLP-1 target that’s showing remarkable results in preliminary trials . This treatment works by imitating natural hormones to affect appetite and increase feelings of satiety, ultimately contributing to considerable fat